Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctioninositol 1,4,5 trisphosphate binding

PLCD1 ITPR2

8.61e-0514202GO:0070679
GeneOntologyMolecularFunctionintracellularly ligand-gated monoatomic ion channel activity

CFTR ITPR2

4.94e-0433202GO:0005217
GeneOntologyMolecularFunctionaminoacyl-tRNA ligase activity

DALRD3 KARS1

8.01e-0442202GO:0004812
GeneOntologyMolecularFunctionligase activity, forming carbon-oxygen bonds

DALRD3 KARS1

8.01e-0442202GO:0016875
GeneOntologyMolecularFunctiontRNA binding

DALRD3 KARS1

3.39e-0387202GO:0000049
GeneOntologyMolecularFunctionscaffold protein binding

KARS1 ITPR2

3.86e-0393202GO:0097110
GeneOntologyMolecularFunctionalcohol binding

PLCD1 ITPR2

4.62e-03102202GO:0043178
GeneOntologyMolecularFunctionphospholipase activity

PLCD1 ABHD6

5.74e-03114202GO:0004620
DomainMIR

POMT2 ITPR2

4.88e-0510202PS50919
DomainMIR

POMT2 ITPR2

4.88e-0510202PF02815
DomainMIR

POMT2 ITPR2

4.88e-0510202SM00472
DomainMIR_motif

POMT2 ITPR2

4.88e-0510202IPR016093
PathwayKEGG_MEDICUS_REFERENCE_CA2_PLCD_ITPR_SIGNALING_PATHWAY

PLCD1 ITPR2

2.30e-056182M47960
Pubmed

Mamld1 knockdown reduces testosterone production and Cyp17a1 expression in mouse Leydig tumor cells.

CYP17A1 NOTCH1

1.88e-06420221559465
Pubmed

Growth Arrest Specific 2 (GAS2) is a Critical Mediator of Germ Cell Cyst Breakdown and Folliculogenesis in Mice.

CYP17A1 NOTCH1

3.14e-06520227734842
Pubmed

Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis.

DCAF1 FANCI NUP214 ITPR2

1.93e-0528520432838362
Pubmed

Vpr-host interactions during HIV-1 viral life cycle.

DCAF1 KARS1

2.44e-051320221318276
Pubmed

Genome-wide identification of FOXL2 binding and characterization of FOXL2 feminizing action in the fetal gonads.

CYP17A1 ITPR2

5.34e-051920230212841
Pubmed

Genome-wide association study reveals genetic risk underlying Parkinson's disease.

CYP17A1 FAM47E

5.93e-052020219915575
Pubmed

Human immunodeficiency virus type 1 Vpr: functions and molecular interactions.

DCAF1 KARS1

5.93e-052020219458171
Pubmed

Release of calcium from inositol 1,4,5-trisphosphate receptor-regulated stores by HIV-1 Tat regulates TNF-alpha production in human macrophages.

PLCD1 ITPR2

8.61e-052420210843712
Pubmed

Cullin 1 (CUL1) Promotes Primary Ciliogenesis through the Induction of Ubiquitin-Proteasome-Dependent Dvl2 Degradation.

DCAF1 FANCI NUP214

8.83e-0515220334299191
Pubmed

Tcf4 Regulates Synaptic Plasticity, DNA Methylation, and Memory Function.

S1PR5 HTR2C

1.35e-043020227568567
Pubmed

Isolation and Characterization of Fetal Leydig Progenitor Cells of Male Mice.

CYP17A1 NOTCH1

2.07e-043720226697723
Pubmed

MAP4K Interactome Reveals STRN4 as a Key STRIPAK Complex Component in Hippo Pathway Regulation.

DCAF1 MRPS16 MAP4K2

2.49e-0421620332640226
Pubmed

Comparative mapping of 50 human chromosome 9 loci in the laboratory mouse.

NOTCH1 NUP214

4.25e-04532027774911
Pubmed

A large-scale candidate gene association study of age at menarche and age at natural menopause.

INHBC CYP17A1 HTR2C

5.05e-0427520320734064
Pubmed

Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication.

NUP214 KARS1 AMDHD2

5.48e-0428320318854154
CytobandEnsembl 112 genes in cytogenetic band chr3p21

DCAF1 DALRD3

8.27e-03316202chr3p21
CytobandEnsembl 112 genes in cytogenetic band chr9q34

NOTCH1 NUP214

8.73e-03325202chr9q34
Drug3 PS

CFTR ABHD6

7.32e-065202CID000007784
DrugPyrvinium pamoate [3546-41-6]; Down 200; 3.4uM; PC3; HT_HG-U133A

DCAF1 POMT2 DALRD3 NOTCH1

2.27e-051952046339_DN
Drug(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A

POMT2 PLCD1 NUP214 ITPR2

2.27e-051952043893_DN
DrugBenperidol [2062-84-2]; Down 200; 10.4uM; HL60; HT_HG-U133A

CYP17A1 PLCD1 NUP214 ITPR2

2.27e-051952042475_DN
DrugClofazimine [2030-63-9]; Up 200; 8.4uM; MCF7; HT_HG-U133A

DCAF1 POMT2 MAP4K2 PLCD1

2.32e-051962045642_UP
DrugPentolinium bitartrate [52-62-0]; Up 200; 7.4uM; MCF7; HT_HG-U133A

POMT2 CYP17A1 PLCD1 NUP214

2.36e-051972042305_UP
DrugLovastatin [75330-75-5]; Down 200; 9.8uM; HL60; HT_HG-U133A

CYP17A1 PLCD1 ITPR2 AMDHD2

2.36e-051972042494_DN
DrugColistin sulfate [1264-72-8]; Down 200; 3uM; HL60; HT_HG-U133A

CYP17A1 PLCD1 NUP214 ITPR2

2.36e-051972042491_DN
Drugnordihydroguaiaretic acid; Up 200; 1uM; MCF7; HT_HG-U133A

POMT2 MAP4K2 CYP17A1 ABHD6

2.41e-051982041648_UP
DrugPyrilamine maleate [59-33-6]; Down 200; 10uM; PC3; HT_HG-U133A

MAP4K2 NOTCH1 ITPR2 ABHD6

2.41e-051982045869_DN
DrugDihydrostreptomycin sulfate [5490-27-7]; Down 200; 2.8uM; PC3; HT_HG-U133A

POMT2 MAP4K2 NOTCH1 ABHD6

2.41e-051982042074_DN
DrugTiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Down 200; 6.4uM; PC3; HT_HG-U133A

DCAF1 POMT2 DALRD3 PLCD1

2.41e-051982042096_DN
DrugSulpiride [15676-16-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A

MAP4K2 NUP214 ITPR2 HTR2C

2.46e-051992044389_UP
DrugNSC605986

CFTR ABHD6

4.01e-0511202CID000354376
DrugNSC35770

INHBC NUP214 HTR2C

4.56e-0580203CID000002800
DrugSulfonamides

NOTCH1 CFTR

6.63e-0514202ctd:D013449
DrugLorcaserin A

HTR2C ABHD6

1.38e-0420202CID010465263
Drugbenzimidazolone

CFTR HTR2C

1.52e-0421202CID000088638
Drug2-octanol

CFTR ABHD6

1.52e-0421202CID000020083
Drugcarboxymethyl-CoA

PLCD1 ABHD6

1.68e-0422202CID000444878
Drugpanorama

CFTR ABHD6

1.68e-0422202CID000008174
DrugAC1L3W0F

CFTR ABHD6

1.83e-0423202CID000123172
Drugphentermine

HTR2C ABHD6

2.73e-0428202CID000004771
DrugCyclosporin A [59865-13-3]; Up 200; 3.4uM; MCF7; HT_HG-U133A

POMT2 PLCD1 ABHD6

4.62e-041752033267_UP
DrugBenzethonium chloride [121-54-0]; Up 200; 9uM; MCF7; HT_HG-U133A

MAP4K2 NUP214 HTR2C

5.02e-041802036070_UP
DrugIsoetharine mesylate salt [7279-75-6]; Up 200; 12uM; HL60; HT_HG-U133A

POMT2 PLCD1 NUP214

5.35e-041842032711_UP
Drug5707885; Up 200; 50uM; PC3; HT_HG-U133A

POMT2 PLCD1 ITPR2

5.52e-041862036438_UP
Drugsibutramine

HTR2C ABHD6

5.60e-0440202CID000005210
Drug11-deoxy-16,16-dimethyl Prostaglandin E2; Up 200; 10uM; PC3; HT_HG-U133A

DALRD3 NOTCH1 PLCD1

5.96e-041912037538_UP
DrugLuteolin [491-70-3]; Down 200; 14uM; PC3; HT_HG-U133A

POMT2 DALRD3 PLCD1

5.96e-041912036658_DN
DrugDrofenine hydrochloride [548-66-3]; Up 200; 11.4uM; MCF7; HT_HG-U133A

DCAF1 MAP4K2 CFTR

5.96e-041912036776_UP
Drugrosiglitazone maleate; Up 200; 10uM; PC3; HG-U133A

POMT2 NOTCH1 ABHD6

5.96e-04191203430_UP
DrugNitrarine dihydrochloride [20069-05-0]; Up 200; 10.6uM; PC3; HT_HG-U133A

POMT2 NUP214 AMDHD2

6.05e-041922037382_UP
DrugButacaine [149-16-6]; Down 200; 13uM; MCF7; HT_HG-U133A

DALRD3 ITPR2 ABHD6

6.05e-041922033469_DN
DrugTranylcypromine hydrochloride [1986-47-6]; Down 200; 23.6uM; PC3; HT_HG-U133A

DALRD3 PLCD1 AMDHD2

6.05e-041922032101_DN
DrugSyrosingopine [84-36-6]; Up 200; 6uM; MCF7; HT_HG-U133A

DCAF1 CYP17A1 NUP214

6.05e-041922036213_UP
DrugSolasodine [126-17-0]; Down 200; 9.6uM; MCF7; HT_HG-U133A

POMT2 ITPR2 ABHD6

6.05e-041922036025_DN
DrugCimetidine [51481-61-9]; Down 200; 15.8uM; MCF7; HT_HG-U133A

DALRD3 CYP17A1 NOTCH1

6.15e-041932031464_DN
DrugIocetamic acid [16034-77-8]; Down 200; 6.6uM; MCF7; HT_HG-U133A

DALRD3 PLCD1 ABHD6

6.15e-041932034425_DN
DrugFluvastatin sodium salt [93957-55-2]; Up 200; 9.2uM; MCF7; HT_HG-U133A

DCAF1 POMT2 NUP214

6.15e-041932033370_UP
DrugRemoxipride Hydrochloride [73220-03-8]; Down 200; 9.8uM; HL60; HT_HG-U133A

DCAF1 PLCD1 ABHD6

6.15e-041932033124_DN
DrugParbendazole [14255-87-9]; Down 200; 16.2uM; PC3; HT_HG-U133A

ITPR2 AMDHD2 ABHD6

6.15e-041932033799_DN
DrugTetrahydroalstonine [6474-90-4]; Up 200; 11.4uM; MCF7; HT_HG-U133A

FANCI DALRD3 ITPR2

6.15e-041932032748_UP
DrugMexiletine hydrochloride [5370-01-4]; Down 200; 18.6uM; MCF7; HT_HG-U133A

POMT2 PLCD1 ITPR2

6.15e-041932033973_DN
Drugara-Hx

MAP4K2 KARS1 HTR2C

6.15e-04193203CID000000804
DrugCeforanide [60925-61-3]; Down 200; 7.6uM; PC3; HT_HG-U133A

POMT2 PLCD1 ITPR2

6.15e-041932036751_DN
Drugdiamino sulfate

NUP214 KARS1 ABHD6

6.15e-04193203CID006327663
Drugheptanol

CFTR ABHD6

6.18e-0442202CID000008129
DrugBacampicillin hydrochloride [37661-08-8]; Down 200; 8uM; MCF7; HT_HG-U133A

CYP17A1 PLCD1 CFTR

6.24e-041942034417_DN
DrugSulfamonomethoxine [1220-83-3]; Down 200; 14.2uM; HL60; HT_HG-U133A

MAP4K2 ITPR2 AMDHD2

6.24e-041942032742_DN
Drug2-propylpentanoic acid; Up 200; 50uM; MCF7; HT_HG-U133A_EA

NOTCH1 ITPR2 ABHD6

6.24e-041942031060_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A

ITPR2 AMDHD2 ABHD6

6.24e-041942032993_UP
DrugRifampicin [13292-46-1]; Down 200; 4.8uM; MCF7; HT_HG-U133A

DCAF1 CYP17A1 NUP214

6.24e-041942034126_DN
DrugFusaric acid [536-69-6]; Up 200; 22.4uM; HL60; HT_HG-U133A

MAP4K2 PLCD1 ABHD6

6.24e-041942031308_UP
DrugHalcinonide [3093-35-4]; Up 200; 8.8uM; PC3; HT_HG-U133A

POMT2 NUP214 CFTR

6.24e-041942037379_UP
DrugSulmazole [73384-60-8]; Down 200; 14uM; HL60; HT_HG-U133A

CYP17A1 ITPR2 ABHD6

6.33e-041952032153_DN
DrugMeptazinol hydrochloride [59263-76-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A

POMT2 INHBC ABHD6

6.33e-041952037326_UP
DrugAtovaquone [95233-18-4]; Down 200; 11uM; PC3; HT_HG-U133A

MAP4K2 NOTCH1 NUP214

6.33e-041952034201_DN
DrugDeoxycorticosterone [64-85-7]; Up 200; 12.2uM; HL60; HT_HG-U133A

CFTR AMDHD2 ABHD6

6.33e-041952033099_UP
DrugAdenosine 5'-monophosphate monohydrate [18422-05-4]; Down 200; 11uM; MCF7; HT_HG-U133A

POMT2 CYP17A1 ITPR2

6.33e-041952033237_DN
DrugCP-320650-01 [172079-28-6]; Up 200; 10uM; PC3; HT_HG-U133A

POMT2 CYP17A1 PLCD1

6.33e-041952034557_UP
DrugKaempferol [520-18-3]; Up 200; 14uM; HL60; HT_HG-U133A

DCAF1 CFTR ITPR2

6.33e-041952036157_UP
DrugPhenformin hydrochloride [834-28-6]; Up 200; 16.6uM; PC3; HT_HG-U133A

CFTR ITPR2 AMDHD2

6.43e-041962034283_UP
DrugMefloquine hydrochloride [51773-92-3]; Down 200; 9.6uM; PC3; HT_HG-U133A

CYP17A1 NOTCH1 ABHD6

6.43e-041962035724_DN
DrugRetinoic acid [302-79-4]; Down 200; 13.4uM; PC3; HT_HG-U133A

DCAF1 POMT2 PLCD1

6.43e-041962035767_DN
Drug6-mercaptopurine monohydrate; Up 200; 10uM; PC3; HG-U133A

CYP17A1 NUP214 ABHD6

6.43e-04196203667_UP
DrugMethiazole; Down 200; 15uM; PC3; HT_HG-U133A

DCAF1 POMT2 NOTCH1

6.43e-041962033796_DN
DrugRiluzole hydrochloride; Up 200; 14.8uM; MCF7; HT_HG-U133A

DCAF1 INHBC CYP17A1

6.43e-041962032295_UP
Drug2-propylpentanoic acid; Up 200; 500uM; HL60; HT_HG-U133A

POMT2 ITPR2 ABHD6

6.43e-041962031181_UP
DrugDelcorine; Down 200; 8.4uM; MCF7; HT_HG-U133A

POMT2 PLCD1 ITPR2

6.43e-041962033613_DN
DrugKhellin [82-02-0]; Down 200; 15.4uM; MCF7; HT_HG-U133A

CYP17A1 PLCD1 NUP214

6.43e-041962034987_DN
Drug(R)-(+)-Atenolol [56715-13-0]; Down 200; 15uM; HL60; HT_HG-U133A

DALRD3 NUP214 ABHD6

6.43e-041962032496_DN
DrugAminophylline [317-34-0]; Down 200; 9.6uM; MCF7; HT_HG-U133A

CYP17A1 NOTCH1 PLCD1

6.43e-041962033374_DN
DrugMethacycline hydrochloride [3963-95-9]; Up 200; 8.4uM; MCF7; HT_HG-U133A

POMT2 NUP214 CFTR

6.43e-041962037321_UP
DrugLomefloxacin hydrochloride [98079-52-8]; Up 200; 10.4uM; PC3; HT_HG-U133A

CYP17A1 ITPR2 AMDHD2

6.43e-041962034281_UP
DrugAmpyrone [83-07-8]; Up 200; 19.6uM; MCF7; HT_HG-U133A

DCAF1 CFTR ITPR2

6.43e-041962036845_UP
DrugTetracycline hydrochloride [64-75-5]; Down 200; 8.4uM; PC3; HT_HG-U133A

DALRD3 NOTCH1 ITPR2

6.43e-041962035757_DN
DrugTestosterone propionate [57-85-2]; Down 200; 11.6uM; MCF7; HT_HG-U133A

POMT2 ITPR2 ABHD6

6.43e-041962035636_DN
DrugMoricizine hydrochloride [31883-05-3]; Down 200; 8.6uM; PC3; HT_HG-U133A

CYP17A1 PLCD1 ITPR2

6.43e-041962037297_DN
DrugHeliotrine [303-33-3]; Down 200; 12.8uM; MCF7; HT_HG-U133A

POMT2 NOTCH1 ITPR2

6.43e-041962034739_DN
DrugPentetic acid [67-43-6]; Up 200; 10.2uM; MCF7; HT_HG-U133A

POMT2 INHBC PLCD1

6.43e-041962035629_UP
DrugNicergoline; Down 200; 8.2uM; PC3; HT_HG-U133A

DCAF1 POMT2 PLCD1

6.43e-041962032058_DN
DrugBaclofen (R,S) [1134-47-0]; Up 200; 18.8uM; HL60; HG-U133A

DCAF1 CYP17A1 PLCD1

6.43e-041962032036_UP
DrugTorsemide [56211-40-6]; Up 200; 11.4uM; MCF7; HT_HG-U133A

CYP17A1 PLCD1 NUP214

6.43e-041962033517_UP
DrugIsosorbide dinitrate [87-33-2]; Down 200; 17uM; MCF7; HT_HG-U133A

POMT2 DALRD3 ABHD6

6.43e-041962036038_DN
DrugNS-398; Up 200; 10uM; MCF7; HT_HG-U133A

CYP17A1 PLCD1 ITPR2

6.43e-041962036911_UP
DrugAlcuronium chloride [15180-03-7]; Down 200; 5.4uM; MCF7; HT_HG-U133A

POMT2 CYP17A1 CFTR

6.43e-041962034409_DN
DrugGabazine [105538-73-6]; Up 200; 10.8uM; MCF7; HT_HG-U133A

DALRD3 PLCD1 ABHD6

6.43e-041962033253_UP
DrugN6-methyladenosine [1867-73-8]; Down 200; 14.2uM; PC3; HT_HG-U133A

DCAF1 PLCD1 NUP214

6.52e-041972036732_DN
DrugS-(+)-ibuprofen [51146-56-6]; Up 200; 19.4uM; MCF7; HT_HG-U133A

POMT2 INHBC ITPR2

6.52e-041972036471_UP
DrugMethyldopa (L,-) [555-30-6]; Up 200; 19uM; MCF7; HT_HG-U133A

POMT2 PLCD1 ITPR2

6.52e-041972035637_UP
DrugCortisone [53-06-5]; Up 200; 11uM; MCF7; HT_HG-U133A

POMT2 INHBC PLCD1

6.52e-041972037458_UP
Drug3-alpha-Hydroxy-5-beta-androstan-17-one [53-42-9]; Up 200; 13.8uM; MCF7; HT_HG-U133A

MAP4K2 PLCD1 ITPR2

6.52e-041972034764_UP
DrugIsometheptene mucate; Down 200; 8.2uM; HL60; HT_HG-U133A

PLCD1 ITPR2 ABHD6

6.52e-041972033145_DN
DrugHarmalol hydrochloride dihydrate [6028-07-5]; Down 200; 14.6uM; MCF7; HT_HG-U133A

MAP4K2 DALRD3 PLCD1

6.52e-041972032892_DN
DrugTrichlorfon [52-68-6]; Down 200; 15.6uM; PC3; HT_HG-U133A

MAP4K2 CYP17A1 PLCD1

6.52e-041972037287_DN
DrugTolbutamide [64-77-7]; Down 200; 14.8uM; MCF7; HT_HG-U133A

POMT2 MAP4K2 PLCD1

6.52e-041972033886_DN
DrugEtofylline [519-37-9]; Down 200; 17.8uM; PC3; HT_HG-U133A

POMT2 PLCD1 AMDHD2

6.52e-041972032093_DN
DrugCarisoprodol [78-44-4]; Up 200; 15.4uM; MCF7; HT_HG-U133A

POMT2 MAP4K2 ABHD6

6.52e-041972034955_UP
DrugFuraltadone hydrochloride [3759-92-0]; Up 200; 11uM; MCF7; HT_HG-U133A

PLCD1 NUP214 CFTR

6.52e-041972033413_UP
DiseaseNeuralgia, Supraorbital

CYP17A1 HTR2C

5.21e-0516202C0038870
DiseaseNeuralgia, Iliohypogastric Nerve

CYP17A1 HTR2C

5.21e-0516202C0423712
DiseaseNeuralgia, Perineal

CYP17A1 HTR2C

5.21e-0516202C0423711
DiseaseNeuralgia

CYP17A1 HTR2C

5.21e-0516202C0027796
DiseaseNeuralgia, Atypical

CYP17A1 HTR2C

5.21e-0516202C0234247
DiseaseNeuralgia, Stump

CYP17A1 HTR2C

5.21e-0516202C0234249
DiseaseParoxysmal Nerve Pain

CYP17A1 HTR2C

5.21e-0516202C0751373
DiseaseNerve Pain

CYP17A1 HTR2C

5.21e-0516202C0751372
DiseaseNeuralgia, Ilioinguinal

CYP17A1 HTR2C

5.21e-0516202C0751371
DiseaseNeuralgia, Vidian

CYP17A1 HTR2C

5.21e-0516202C0042656
Diseasealkaline phosphatase measurement

INHBC MAP4K2 DALRD3 NOTCH1 FAM47E

4.80e-041015205EFO_0004533
DiseaseMale sterility

CYP17A1 CFTR

4.83e-0448202C0917731
DiseaseMale infertility

CYP17A1 CFTR

4.83e-0448202C0021364
DiseaseSubfertility, Male

CYP17A1 CFTR

4.83e-0448202C0848676
DiseaseChildhood Acute Lymphoblastic Leukemia

NOTCH1 NUP214

5.67e-0452202C0023452
DiseasePrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

NOTCH1 NUP214

5.89e-0453202C1961099

Protein segments in the cluster

PeptideGeneStartEntry
GRPGHKPSILMLHGF

ABHD6

66

Q9BV23
LLLHPAIFGLHHIGM

CFTR

136

P13569
LMLLHGHTEEPPGLS

HTR2C

246

P28335
MAGHLGAFHPAPLPL

CELF6

226

Q96J87
LIHLIMHDYPPLLSG

ITPR2

1061

Q14571
ELGELQPPLFHLHPM

MAP4K2

206

Q12851
GLLMLEAHHFPGPLL

FANCI

91

Q9NVI1
HPGRADPECMLGHLL

DCAF1

61

Q9Y4B6
LNHLPGMPDTHLGIG

NOTCH1

2231

P46531
PLHIAGMPGIAASFH

INHBC

281

P55103
GLLVPMKFPIHHLAL

NUP214

86

P35658
HAILGPMLLNRPLDG

PLCD1

406

P51178
LVGSLPFLPRHGHMH

CYP17A1

36

P05093
HILGEPRPHLFGQMF

DALRD3

501

Q5D0E6
LGRHPRFHAPMFLLL

S1PR5

61

Q9H228
PMEKLLGLAGFFPLH

MRPS16

86

Q9Y3D3
HKMDLLHENGPRPGL

FAM47E

206

Q6ZV65
HPPLGKMLIGLAGYL

POMT2

106

Q9UKY4
LSPCLHMLPHLHFGL

KARS1

206

Q15046
AMLPFHHRDPGIVGL

AMDHD2

236

Q9Y303